This result led to the FDA approval of enasidenib for relapsed or refractory IDH2-mutant AML in 2017 [50], and also to the development of other trials evaluating this drug in various AML subpopulations and advanced solid tumors. Here, IDH2 is linked to acute myeloid leukemia.